HPLC traces at 230nm absorption for PDP3 and PDP-Nal after the indicated treatments (x-axis: time; y-axis: absorption units). Illumination with UV light 5 minutes at 365nm; 24 at room temperature (r.t.) under daylight. Detailed information about antibodies is given in the section "SDS-PAGE and Western Blot".
Peptide Synthesis
Peptide synthesis was carried out as described previously. S1 Briefly, peptides were synthesized on a Multisyntech peptide synthesizer following a standard fluorenylmethoxycarbonyl (Fmoc) solid-phase peptide synthesis protocol: double couplings, followed by capping and Fmoc deprotection. Double couplings were carried out with Fmoc-amino acids (5 eq), diisopropylethylamine (DIEA, 6 eq), 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU, 5 eq), and 1-hydroxybenzotriazol (HOBt, 5 eq) in 1 ml N,N-dimethyl formamide (DMF) using Rink amide resin. Capping and N-terminal acetylation was carried out using 1 ml 1:9
(vol:vol) acetic anhydride:pyridine, and Fmoc deprotection was accomplished with 20% piperidine. The peptides were cleaved from resin using a cleavage cocktail (95% trifluoroacetic acid (TFA), 2.5% triisopropylsilane (TIS), 2.5% H 2 O), etherprecipitated, purified with high-performance liquid chromatography (HPLC, Shimadzu LCMS-2010EV), and analyzed by matrix-assisted laser desorption/ionization (MALDI micro MX, Waters) mass spectrometry.
The 5-carboxyfluorescein labelling was also carried out as described previously.
S1
Briefly, the N-terminally unprotected peptide linked C-terminally to the resin was swollen in DMF for 30 min. A solution of 5-carboxyfluorescein (3 eq), 1-hydroxy-7-azabenzotriazole (HOAt, 3 eq), 2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU, 3 eq), and DIEA (6 eq) in 2 ml DMF was added to the resin and shaken at room temperature for 3 h. The coupling was repeated once. Purification and analysis was done as described above.
Recombinant Proteins
Recombinant PP1α catalytic subunit was purified by the Protein Expression and Purification Core Facility at EMBL, Heidelberg, according to a published protocol.
S1
To obtain recombinant Inhibitor-2 (PPP1R2, I-2), pETM-20-His-TEV-PPP1R2 was transformed into BL21 and grown on Amp-containing LB plates. Expression was induced by addition of 0.1mM IPTG to a 1L culture at an OD of 0.7 at 37°C for 4h.
Cells were harvested (4°C, 30min, 2400rpm) and resuspended in 10mL lysis buffer (50mM Tris, 500mM NaCl, 30mM imidazole, 1x protease inhibitor cocktail and lysed by sonication on ice (pulse-mode, 1sec on 1sec off, 3 cycles of 6min). After a spindown (1h, 15000rcf) His-tagged was purified by loading on a nickel-charged IMAC column (HisTrap, GE Healthcare). The column was washed with lysis buffer and recombinant I-2 was eluted by 250mM imidazole. After dialysis in 50mM TrisHCl, 500mM NaCl overnight at 4°C, protein was incubated with TEV protease for 12h at 4°C, and loaded onto Ni-column (see above). Flow-through containing the recombinant protein without His-tag was fractionated and fractions were analyzed on an SDS-gel by subsequent Coomassie-staining. Protein was further concentrated to ~20µM, and stored in 50mM TrisHCl, 500mM NaCl, 20% glycerol at -80°C.
Cell Line
U2OS human female osteosarcoma cells were cultured at 37°C in a humidified incubator under an atmosphere of 5% CO 2 . The cells were grown in Dulbecco's modified Eagle's medium (DMEM) containing 1 g/L glucose, 10% (v/v) fetal bovine serum (FBS), 1% (v/v) penicillin/streptomycin and 2 mM L-glutamine.
SDS-PAGE and Western blotting
All protein samples were resolved by using precast NuPAGE 4-12% or 12% Bis-Tris
Gels ( For figures 3A and 3B, images were acquired using Kodak BioMax MR (high resolution radioisotope and chemiluminescent) from Sigma-Aldrich, and Amersham
Hyperfilm ECL (high performance chemiluminescence film) from GE Healthcare
